FDA Reclassifies Pelvic Mesh Devices As High-Risk, Orders Premarket Approval
SILVER SPRING, Md. — The Food and Drug Administration on Jan. 4 issued final orders reclassifying pelvic mesh devices intended to treat pelvic organ prolapse (POP) from moderate-risk Class II to...To view the full article, register now.
Already a subscriber? Click here to view full article